GB2524474B - Composition and use of lactobacillus reuteri GMNL-89 in treating type 2 diabetes - Google Patents
Composition and use of lactobacillus reuteri GMNL-89 in treating type 2 diabetesInfo
- Publication number
- GB2524474B GB2524474B GB1404044.8A GB201404044A GB2524474B GB 2524474 B GB2524474 B GB 2524474B GB 201404044 A GB201404044 A GB 201404044A GB 2524474 B GB2524474 B GB 2524474B
- Authority
- GB
- United Kingdom
- Prior art keywords
- diabetes
- composition
- lactobacillus reuteri
- treating type
- reuteri gmnl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1404044.8A GB2524474B (en) | 2014-03-07 | 2014-03-07 | Composition and use of lactobacillus reuteri GMNL-89 in treating type 2 diabetes |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1404044.8A GB2524474B (en) | 2014-03-07 | 2014-03-07 | Composition and use of lactobacillus reuteri GMNL-89 in treating type 2 diabetes |
Publications (3)
Publication Number | Publication Date |
---|---|
GB201404044D0 GB201404044D0 (en) | 2014-04-23 |
GB2524474A GB2524474A (en) | 2015-09-30 |
GB2524474B true GB2524474B (en) | 2018-01-31 |
Family
ID=50554684
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB1404044.8A Active GB2524474B (en) | 2014-03-07 | 2014-03-07 | Composition and use of lactobacillus reuteri GMNL-89 in treating type 2 diabetes |
Country Status (1)
Country | Link |
---|---|
GB (1) | GB2524474B (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107475117A (en) * | 2017-07-03 | 2017-12-15 | 桐乡恒基生物股份有限公司 | A kind of freeze drying protectant for lactobacillus reuteri and lyophilized store method |
TWI709374B (en) * | 2019-06-14 | 2020-11-11 | 豐華生物科技股份有限公司 | Use of food composition and pharmaceutical composition with strains of lactic acid bacteria for modulating blood glucose |
CN114990004B (en) * | 2022-04-19 | 2023-09-15 | 尚品健康科技(青岛)有限公司 | Secretory immunoglobulin A-packaged lactobacillus reuteri and application thereof in preventing and treating gestational diabetes |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004014403A1 (en) * | 2002-08-09 | 2004-02-19 | Bioneer Corporation | Microorganisms for inhibiting obesity and diabetes mellitus |
WO2010124387A1 (en) * | 2009-05-01 | 2010-11-04 | Micropharma Limited | Bacterial compositions for prophylaxis and treatment of degenerative disease |
US8298526B2 (en) * | 2010-06-02 | 2012-10-30 | Genmont Biotech Inc. | Lactobacillus strain, composition and use thereof for improving the syndrome of diabetes and complication thereof |
-
2014
- 2014-03-07 GB GB1404044.8A patent/GB2524474B/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004014403A1 (en) * | 2002-08-09 | 2004-02-19 | Bioneer Corporation | Microorganisms for inhibiting obesity and diabetes mellitus |
WO2010124387A1 (en) * | 2009-05-01 | 2010-11-04 | Micropharma Limited | Bacterial compositions for prophylaxis and treatment of degenerative disease |
US8298526B2 (en) * | 2010-06-02 | 2012-10-30 | Genmont Biotech Inc. | Lactobacillus strain, composition and use thereof for improving the syndrome of diabetes and complication thereof |
Non-Patent Citations (1)
Title |
---|
Nutrition & Metabolism, vol. 10, No. 1, 2013, page 35 * |
Also Published As
Publication number | Publication date |
---|---|
GB2524474A (en) | 2015-09-30 |
GB201404044D0 (en) | 2014-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20190369T1 (en) | Dihydrobenzofuran compounds useful in the treatment of diabetes and obesity | |
PL3212208T3 (en) | Use of l. reuteri for prevention or treatment of microbiota dysbiosis in early life | |
IL247775A0 (en) | In vivo and in vitro use of graphene | |
SG11201703298SA (en) | Activated bifidobacteria and methods of use thereof | |
GB201411197D0 (en) | Composition and use thereof | |
PL3018183T3 (en) | Haloolefin-based composition and use thereof | |
GB201411496D0 (en) | Use of 7-Oh-Cannabidiol (7-Oh-CBD) and/or 7-Oh-Cannabidvarin (7-Oh-CBDV) in the treatment of epilepsy | |
HK1218312A1 (en) | Composition and use thereof in sequence determination and mutation detection | |
ZA201900869B (en) | Use of probiotics in the treatment and/or prevention of atopic dermatitis | |
HK1245658A1 (en) | Nutritional composition useful in the treatment of ibd patients | |
ZA201704726B (en) | Peptides and their use in the treatment of skin | |
GB2548930B (en) | Heat-inactivated Lactobacillus rhamnosis GMNL-464 for use in the prevention of halitosis | |
PL3157354T3 (en) | Composition in the form of compacted particles and use thereof | |
RS64392B1 (en) | Preparation comprising lactobacillus reuteri and citrate for medical use | |
GB2524474B (en) | Composition and use of lactobacillus reuteri GMNL-89 in treating type 2 diabetes | |
GB201411196D0 (en) | Composition and use thereof | |
HUE045831T2 (en) | New lactobacillus plantarum strain amt14 and composition containing the strain of lactobacillus plantarum amt14 | |
HK1258843A1 (en) | Glycolipid compounds and their uses in the treatment of tumours | |
HK1244821A1 (en) | Peptides for use in treatment and diagnosis of type 1 diabetes | |
PL3454873T3 (en) | Probiotic composition and uses thereof | |
GB201502240D0 (en) | Composition and use of lactobacillus reuteri GMNL-263 in decreasing blood lipid levels | |
GB2530711B (en) | Security composition and use thereof | |
GB201502565D0 (en) | Composition and use in treatment of a detached retina | |
ZA201403582B (en) | Composition for use in treatment of anemia and low blood pressure | |
GB201409978D0 (en) | Novel compounds and their use in therapy |